Depakote Lawsuit Over Spina Bifida Birth Defect Results in $15M Jury Award

A St. Louis jury has determined that AbbVie should pay $15 million to the family of a Minnesota girl born with spina bifida, indicating that the drug maker failed to adequately warn about the risk of birth defects from Depakote use during pregnancy.

The verdict came in a product liability lawsuit brought by the family of 12 year-old Maddison Schmidt, who was born with numerous health complications, which were allegedly caused by her mother’s use of the anti-seizure medication Depakote before she was born.

The jury determined that AbbVie, which owns Depakote after Abbott Laboratories spun off the company, should pay $15 million in compensatory damages to cover Schmidt’s life-long medical costs, pain and suffering and other expenses. AbbVie may face additional punitive damages during a second phase of the trial, if the jury decides to award additional damages to punish the company for recklessly endangering unborn children.

Sports-Betting-Addiction-Lawsuits
Sports-Betting-Addiction-Lawsuits

AbbVie faces a number of similar Depakote lawsuits brought by families throughout the U.S., which raise similar allegations that inadequate warnings about the pregnancy risks were provided for women and the medical community.

Depakote Birth Defect Risks

Depakote was approved in the United States in 1978 for treatment of certain forms of epilepsy. However, Depakote pregnancy risks have been associated with the development of severe birth defects and malformations, including spina bifida, cleft palate, abnormal skull development, malformed limbs, holes in the heart and urinary tract problems; especially when the drug is taken during the first 28 days, when neural tube closure and other critical formations are taking place.

In 2006, the FDA added a “black box” warning about the potential Depakote birth defects side effects, after a study found that 20% of pregnant mothers who gave birth while on Depakote had a child with malformations or a birth defect.

In May 2013, the FDA put new restrictions on Depakote pregnancy use, contraindicating it for pregnant women, but only when it was used for the treatment of migraines. The agency did not contraindicate it for pregnant women using it to treat epilepsy. The FDA changed all valproate-based drugs from a class “D” to a class “X” pregnancy drug, but only as they pertain to migraines.

Before the drug’s patent expired in 2007, Depakote was a blockbuster drug generating about $1.5 billion in annual sales for AbbVie’s predecessor.

Written by: Irvin Jackson

Senior Legal Journalist & Contributing Editor

Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends.




0 Comments


Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

MORE TOP STORIES

Roblox is facing a lawsuit from a Georgia mother who alleges the platform’s failure to implement adequate child safety measures allowed online predators to groom her young son.
Hearings over the validity of expert witnesses in hair relaxer cancer lawsuits will begin on April 1, 2026, when plaintiffs’ experts must convince the judge that their testimony linking the products to cancer is scientifically reliable enough to be presented to juries.